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Chronic, low-grade inflammation of visceral adipose tissue, and systemically, is a critical link between recent
strikingly parallel rises in the incidence of obesity and type 2 diabetes. Macrophages have been recognized
for some time to be critical participants in obesity-induced inflammation of adipose tissue. Of late, a score of
other cell types of the innate and adaptive arms of the immune system have been suggested to play a positive
or negative role in adipose tissue infiltrates. This piece reviews the existing data on these new participants;
discusses experimental uncertainties, inconsistencies, and complexities; and puts forward a minimalist
synthetic scheme.Classic studies, now decades old, revealed that visceral
adipose tissue (VAT) is a site where cells andmolecules that con-
trol metabolism and immunity interplay, with important conse-
quences for organismal homeostasis. Twenty years ago,
Hotamisligil et al. demonstrated that tumor necrosis factor a
(TNF-a) messenger RNA (mRNA) and protein were induced in
the epididymal fat pad of obese rodents and that neutralization
of this cytokine improved their characteristic systemic insulin
resistance (Hotamisligil et al., 1993). Ten years later, two groups
independently reported an impressive accumulation of macro-
phage-associated gene transcripts and of cells expressing the
F4/80 or CD68 marker, presumed to be macrophages, with
increasing adiposity in mice and humans (Xu et al., 2003; Weis-
berg et al., 2003). These studies catalyzed the emerging notion
that chronic, low-grade inflammation is a critical link between
obesity and a spectrum of metabolic abnormalities, including
insulin resistance, type 2 diabetes, and fatty-liver disease. Other
proinflammatory cytokines, notably interleukin-6 (IL-6) and
IL-1b, were eventually implicated (Pradhan et al., 2001; Wen
et al., 2011). And the increase in macrophage representation
was soon found to be accompanied by an altered localization
within the adipose tissue and population evolution to a more
proinflammatory phenotype (Lumeng et al., 2007a, 2007b;
Nguyen et al., 2007). More importantly, the functional relevance
of macrophages and their phenotypic changes was established
through loss- and gain-of-function experiments (e.g., Patsouris
et al., 2008; Weisberg et al., 2006; Kanda et al., 2006; Kamei
et al., 2006). A ‘‘macrophago-centric’’ view of obesity-associ-
ated inflammation reigned for many years, and was recently
reviewed (Osborn and Olefsky, 2012; Chawla et al., 2011).
Of late, there has been growing interest in the roles of addi-
tional members of both the innate and adaptive arms of the
immune system in regulating organismal metabolism. Besides
macrophages, several other immune cell types have been
implicated: mast cells, neutrophils, eosinophils, type 2 innate
lymphoid cells (ILCs), CD8+ and CD4+ T cells, B cells, Foxp3+
regulatory T (Treg) cells, CD48 gd T cells, and natural killer
T cells (NKT cells). What sense are we to make of this intimidat-
ingly complex cast of characters? This piece will lay out the
existing body of data on the participants in obesity-associated
inflammation; address sources of uncertainty, inconsistency,
and complexity; and suggest a minimalist synthetic scheme.The Data: Innate Immune Cells
Immune system cells, above all macrophages, accumulate in the
VAT (in particular, in the epididymal depot) of both lean and
obese individuals. In the lean state, most macrophages have
an anti-inflammatory phenotype, often referred to as ‘‘M2 like’’
or ‘‘alternatively activated’’ (Chawla et al., 2011; Osborn and
Olefsky, 2012; Lumeng et al., 2007a, 2007b; Nguyen et al.,
2007). Their differentiation and/or survival depends on IL-4 and
IL-13; they express the cell-surface markers CD11b, F4/80,
CD301, and CD206, and they secrete anti-inflammatory cyto-
kines such as IL-10 and IL-1 receptor antagonist (IL-1Ra). This
type of macrophage can expand somewhat in the obese state,
but there is a much more striking accumulation of a proinflam-
matory subset, denoted ‘‘M1 like’’ or ‘‘classically activated’’
(Lumeng et al., 2007a, 2007b; Nguyen et al., 2007). These cells,
whose differentiation is promoted by agents such as lipopoly-
saccharide and interferon g (IFN-g), display the marker CD11c
in addition to F4/80 and CD11b and produce proinflammatory
mediators like TNF-a, IL-6, IL-1b, nitric oxide (NO), IL-12, etc.
The M1/M2-like dichotomy is certainly an oversimplification in
this context, as macrophages with intermediate properties
(Shaul et al., 2010; Herrero et al., 2010) or with an extreme
phenotype reminiscent of that of foam cells in atherosclerotic
lesions (Xu et al., 2003; Prieur et al., 2011) are also found in
adipose tissue. As mentioned above, it is by now well estab-
lished that anti-inflammatory macrophages promote local and
systemic insulin sensitivity, while their proinflammatory counter-
parts induce insulin resistance, primarily via secreted mediators
(Osborn and Olefsky, 2012; Chawla et al., 2011). So we will not
dwell on this aspect here.
Additional innate immune cell types, whether of a pro- or
anti-inflammatory nature, have more recently been implicated
in obesity-induced metabolic aberrancies. Mast cells, once
mature, reside in connective and mucosal tissue, where they
are part of an ‘‘early-warning’’ system that infection or injury
has occurred in the vicinity. They contain numerous granules
loaded with preformed mediators, e.g., histamine, serotonin,
heparin, serine proteases, eicosanoids, and cytokines (notably
TNF-a and IL-1b). Uponmast cell activation, all or a select subset
of these mediators are released in a rapid burst, activating the
surrounding vasculature and promoting recruitment of additional
inflammatory cell types. Liu et al. reported that there is a greaterCell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 851
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lean mice and humans (Liu et al., 2009). Genetic mutations at the
Kit locus, which lead to a mast cell deficiency, or pharmacolog-
ical stabilization of mast cell granules resulted in less weight gain
and VATmass on a high-fat diet (HFD), reduction in VAT-resident
macrophages and both adipose-tissue and circulating inflam-
matory mediators, and improvement in several indices of insulin
sensitivity. IL-6 and IFN-g, but not TNF-g, were found to be
important mediators of these effects.
Neutrophils are also early participants in inflammatory reac-
tions, recruited from the circulation by activated endothelium
and/or by tissue-resident macrophages or mast cells. Upon
appropriate stimulation, these short-lived cells release reactive
oxygen species and nitrogen intermediates; degranulate, ex-
pelling serine proteases and other enzymes; and lay down
extracellular traps, or NETs, constituted of extruded webs of
chromatin and serine proteases. Besides being antimicrobial,
these activities amplify inflammatory responses, through recruit-
ment of circulatingmonocytes, for example. Neutrophils begin to
accumulate in the VAT within days after mice are placed on a
HFD, an increase that is sustained for at least 3 months on this
diet (Talukdar et al., 2012; Elgazar-Carmon et al., 2008). Genetic
ablation of the gene encoding the critical neutrophil protease,
elastase, or pharmacological inhibition of its activity substantially
improved the inflammatory tone and metabolic indices of
HFD-fed mice; conversely, injection of recombinant neutrophil
elastase into mice on normal chow (NC) provoked glucose intol-
erance (Talukdar et al., 2012). These alterations did not rely on
body weight and VAT mass changes.
Just as anti-inflammatory macrophages predominate in the
benign infiltrates of VAT in lean mice, particular populations of
anti-inflammatory innate immune cells have been found in these
fat depots. Eosinophils circulate in the immature state and lodge
in a limited range of tissues once mature, a range that is
extended by parasite infection. Their differentiation and activa-
tion are critically dependent on IL-3, IL-5, and granulocyte-
macrophage colony-stimulating factor (GM-CSF). They are
granulocytes, releasing a broad array of pro- and anti-inflamma-
tory mediators, in particular IL-4 and IL-13, known to be crucial
for the differentiation and survival of anti-inflammatory, M2-like
macrophages, including those residing in adipose tissue (Ode-
gaard et al., 2007; Kang et al., 2008). Wu et al.’s attention was
drawn to eosinophils because they found them to be the major
producers of IL-4 in VAT, and their representation in VAT to be
inversely correlated with adiposity (Wu et al., 2011). Mice impov-
erished in eosinophils (a Gata1/ strain), and thereby anti-
inflammatory macrophages, exhibited an increase in body and
VAT weight, as well as more marked glucose intolerance and
insulin resistance, when fed a HFD. Conversely, animals
enriched in eosinophils (an IL-5 transgenic strain), and thus
M2-like macrophages, showed a decline in these parameters.
One step further removed is a recently discovered subset of
innate lymphoid cells termed ILC2s. Like all ILCs, these cells
are characterized by dependence on the transcription factor
Id2 and the cytokine receptor common gamma chain (gc).
They are widely distributed in mammalian tissues, and are
reminiscent of T helper 2 (Th2) cells in their production of the
cytokines IL-5 and IL-13. As IL-13 promotes differentiation of
M2-like macrophages and IL-5 fosters the maturation and852 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.activities of eosinophils, which make most of the IL-4 required
by M2 macrophages, Molofsky et al. were prompted to address
their role in adipose tissue inflammation (Molofsky et al., 2013).
Indeed, they found ILC2s to be the major source of both IL-5
and IL-13 in VAT and their representation in VAT to decline under
a HFD regime. Genetically engineered or cytokine-promoted
increases or decreases in ILC2s led to an enhancement or
reduction, respectively, in VAT eosinophils and anti-inflam-
matory macrophages. These cellular changes were accompa-
nied by the expected alterations in body weight, VAT weight,
and measures of insulin resistance and glucose intolerance
when the mice were put on a HFD.
Together, these results implicate multiple members of the
innate immune system in controlling adipose tissue inflammation
and its downstream consequences—either positively (proinflam-
matory macrophages, mast cells, and neutrophils) or negatively
(anti-inflammatory macrophages, eosinophils, and ILC2s). A
concern that needs to be kept in mind when considering these
findings is that in most cases—even for macrophages—
optimum tools for precisemanipulation of the cell type of interest
are not currently available. Loss- or gain-of-function experi-
ments often rely on manipulation of a factor thought to be
required for differentiation or maintenance of the population
(e.g., cKit for mast cells [Liu et al., 2009] or GATA1 or IL-5 for
eosinophils [Wu et al., 2011; Molofsky et al., 2013]) or an element
thought tomediate one of the population’s critical effectormech-
anisms (e.g., degranulation for mast cells [Liu et al., 2009],
elastase for neutrophils [Elgazar-Carmon et al., 2008], or IL-5
and IL-13 for ILCs [Molofsky et al., 2013]). But these manipula-
tions are seldom exquisitely specific, and so many of them
impact other cells or processes. Neither, in general, do they
encompass the entire potential influence of the targeted cell
type. So it is important to consider to what extent these imper-
fections might compromise the critical conclusions concerning
obesity-associated inflammation. It is also important to be
cognizant of the fact that the list of innate immune cell types
contributing to obesity-associated inflammation might not be
complete. A few classic cell types (e.g., basophils and NK cells)
have not yet been adequately evaluated, and the quite new field
of ILC biology is yielding more and more innate lymphocyte
groupings with activities astonishingly parallel to those of adap-
tive lymphocyte subsets (Klose et al., 2013).
The Data: Adaptive Immune Cells
While it was recognized some time ago that T and B lymphocytes
infiltrate adipose tissue and that their representation correlates
with adiposity (Caspar-Bauguil et al., 2005; Wu et al., 2007;
Rausch et al., 2008; Kintscher et al., 2008; Rocha et al., 2008),
the demonstration that they play important roles, either effector
or regulatory, in organismal metabolism came only quite
recently. Nishimura et al. reported that CD8+ T cells are critical
participants in obesity-induced adipose tissue and systemic
inflammation (Nishimura et al., 2009). Their accumulation after
introduction of a HFDappeared to precede that ofmacrophages,
beginning within 2 weeks. Genetic ablation or monoclonal-
antibody-mediated neutralization of CD8+ T cells in HFD-fed
mice improved VAT inflammatory tone and systemic insulin
sensitivity, under both protective and curative regimes, while
not impacting body or VAT pad weight. Adoptive transfer of
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mutation. Coculture experiments showed that CD8+ T cells can
provoke macrophage migration and differentiation and, in turn,
that adipocytes from obese, but not lean, mice can stimulate
CD8+ cells. Consistent with the latter finding, HFD feeding
resulted in a restriction of the repertoire of CD8+ T cells within
VAT. Several of these findings were confirmed in an independent
study (Yang et al., 2010).
The role of conventional CD4+ Th cells in organismal meta-
bolism seems less clear-cut. Several groups have noted an
enrichment of IFN-g-producing Th1 cells in the VAT of obese
individuals (Feuerer et al., 2009; Zu´n˜iga et al., 2010; Cheng
et al., 2012). And certainly there are abundant cells at that site
potentially capable of antigen presentation to CD4+ T cells
because they express both major histocompatibility complex
(MHC) class II and costimulatory molecules—whether they be
macrophages (Morris et al., 2013) or adipocytes themselves
(Deng et al., 2013; Meijer et al., 2011). Given that IFN-g is an
important proinflammatory cytokine in obesity-induced inflam-
mation and consequent metabolic abnormalities (Rocha et al.,
2008), Th1 cells are likely to join CD8+ T cells as important
effector lymphocytes. On the other hand, Winer et al. have
argued that Th2 cells exert a protective function in these pro-
cesses (Winer et al., 2009). However, such a role remains ques-
tionable because of certain experimental uncertainties in this
study. First, the markers used to identify Th2 cells were not the
best. GATA3 was taken to delineate Th2 cells, but it was subse-
quently demonstrated that the major VAT T cell population ex-
pressing this transcription factor is actually Foxp3+CD4+ Treg
cells (Cipolletta et al., 2012). In addition, the Th2-defining cyto-
kine, IL-4, was not assayed, and it was later shown that by far
the major IL-4 producers in VAT are eosinophils (Wu et al.,
2011). Second, the functional assay used to support a protective
role for Th2 cells, transfer of Foxp3CD4+ cells into lymphopenic
RAG/mice, is known to induce phenotypic changes (in activa-
tion, homing, etc.) in the transferred cells as an accompaniment
to homeostatic proliferation induced by the lymphopenia (Gold-
rath et al., 2004). Thus, a potential role for Th2 cells requires
further substantiation.
Given the demonstrated importance of T lymphocytes in
obesity-associated inflammation, it was logical to explore a
role for B lymphocytes. B cells are present in the VAT of lean
mice and are early participants in the more aggressive infiltrate
induced by HFD (Duffaut et al., 2009; Winer et al., 2011). In
particular, there is an enrichment of cells secreting antibodies
of the immunoglobulin G (IgG) isotype. Winer et al. reported
that B cells exert a potent proinflammatory influence: on HFD,
mice lacking this cell type exhibited the usual weight gain, but
had less inflammatory VAT and improved metabolic indices
(Winer et al., 2011). Reintroduction of splenic B cells from
HFD-fed, but not NC-fed, mice complemented the differences
in B cell null vis-a`-vis wild-type animals, e.g., they induced insulin
resistance in the former case. Strikingly, transfer of serum IgGs
from mice on HFD, but not NC, also provoked insulin resistance
in B cell null mice. In humans, a distinct repertoire of serum IgG
antibodies correlated with a state of insulin resistance, but the
IgGs from both insulin-resistant and -sensitive individuals recog-
nized mostly intracellular proteins from a broad range of tissues.
A more recent study confirmed the proinflammatory impact of Bcells in the HFD setting but did not address a function for IgGs
(DeFuria et al., 2013). It seems clear, then, that B cells play a
proinflammatory role in obesity-induced insulin resistance.
How they exert their impact, in particular the precise function
of IgG antibodies, requires further elucidation. Given that the
‘‘pathogenic’’ antibodies appeared late in the disease process
and that they recognized intracellular proteins likely released
upon cell death, one is tempted to suggest that they are down-
stream players, e.g., by blocking molecules in critical metabolic
pathways or stabilizing anti-inflammatory mediators.
Foxp3+CD4+ Tregs are important negative regulators of VAT
inflammation andmetabolic indices. This cell lineage, delineated
by the Foxp3 transcription factor, controls many types of im-
mune responses, including autoimmunity, allergy, inflammation,
infection, and antitumor immunity (Josefowicz et al., 2012). It can
operate by a variety of mechanisms, such as secretion of inhib-
itory molecules, sequestration of growth factors, metabolic
interference, induction of cell death, etc. Feuerer et al. described
a unique population of Tregs residing in epididymal adipose
tissue of lean mice—special in its transcriptome and clonally
expanded TCR repertoire. In insulin-resistant mouse models of
obesity, there was a striking reduction in VAT-resident, but not
lymphoid-organ, Tregs (Feuerer et al., 2009). Experimental
reduction or augmentation of the Treg compartment led to an
increase or decrease, respectively, of adipose tissue inflamma-
tion and insulin resistance, likely by a combined effect onmacro-
phages, other T cells, and adipocytes. Several of these findings
were later confirmed (Ilan et al., 2010; Eller et al., 2011; Deiuliis
et al., 2011). The unique phenotype of VAT Tregs is driven by
their unusual expression of PPARg (Cipolletta et al., 2012).
Treg-specific ablation of Pparg resulted in a depletion of VAT-
resident, but not lymphoid-organ, Tregs in mice on NC;
conversely, injection of the PPARg agonist, pioglitazone, into
HFD-fed animals specifically expanded the VAT Treg population.
Surprisingly, much of the insulin-sensitizing effect of pioglitazone
disappeared in mice lacking PPARg specifically in Tregs.
Finally, a potential role for adipose-tissue-resident gd T cells
in organismal metabolism was recently evoked (Zu´n˜iga et al.,
2010). IL-17a-deficient mice showed increased adiposity on
both NC and HFD, as well as enhanced glucose intolerance
and insulin resistance. By far the most frequent IL-17-producing
cell type in adipose tissue was found to be CD4–CD8– gd T cells.
In vitro experiments suggested that gd cells can indeed impact
metabolic processes as they suppressed differentiation of the
3T3-L1 preadipocyte cell line and impaired glucose uptake by
mature 3T3-L1 adipocytes. However, mice devoid of gd
T cells did not phenocopy those lacking IL-17a—by way of
explanation, it was argued that IL-17-producing Th (Th17) cells
fulfilled their functional niche. It is necessary to more directly
confirm (or infirm) a regulatory role for gd T cells and to delineate
more precisely which members of this diverse lineage are
involved.
In short, proinflammatory (CD8+ T cells, CD4+ Th1 cells, and B
cells) and anti-inflammatory (Foxp3+CD4+ Tregs) VAT-resident
adaptive immune cells also control inflammatory and metabolic
processes in the VAT and systemically. Further progress awaits
elucidation of their relative importance, how they interplay, and
how they impact innate immune cells, adipocytes and their
precursors, and supporting stromal cells and vasculature.Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 853
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NKT cells straddle innate and adaptive immunity (Rossjohn
et al., 2012). They display cell-surfacemarkers typical of NK cells
(e.g., NK1.1) but also express the antigen-specific receptors
characteristic of T cells (TCRs). Unlike classical T cells, however,
they generally recognize glycolipid antigens in the context of
CD1d, an MHC class Ib molecule. Type 1 or ‘‘invariant’’
NKT cells employ a restricted set of TCRs consisting of a single
a chain (Va14Ja18) and one of a limited number of b chains. Type
2 cells exploit a broader repertoire of TCRs. NKT cells may be
either pro- or anti-inflammatory, rapidly secreting large amounts
of IFN-g or IL-4 upon stimulation.
Given NKT cell recognition of glycolipids and their ready
detection in the VAT of lean mice and humans (Lynch et al.,
2009; Caspar-Bauguil et al., 2005), a flood of investigators
assessed their role in obesity-induced inflammation and its
downstream consequences over the past few years (Ohmura
et al., 2010; Mantell et al., 2011; Kotas et al., 2011;
Satoh et al., 2012; Wu et al., 2012; Ji et al., 2012a, 2012b; Schip-
per et al., 2012; Lynch et al., 2012; Strodthoff et al., 2013)
(Table 1). Loss-of-function experiments generally entailed exam-
ination of mice with null mutations in Cd1d, which impacts all
NK cells, or Ja18, which more specifically targets the type 1
population; gain-of-function studies relied on injection of
alpha-galactosylceramide (aGalCer), a ligand for type-1 cells.
Conclusions from this set of studies have spanned the gamut
from NKT cells positively impacting organismal metabolism, to
having no apparent influence, to negatively affecting metabolic
processes.
How can we reconcile these conflicting outcomes? Close
examination of the details of these studies reveals multiple
experimental issues that could substantially impact results,
including the following:
d Employment of different strategies to manipulate NKT cell
levels—Cd1d/ versus Ja18/ versus aGalCer-injected
mice. Note that the Cd1d/ mutation compromises all
NKT cells, while the Ja18/ mutation and injection of
aGalCer target only type 1 cells. It may also be relevant
that CD1d is expressed by certain parenchymal cells,
notably adipocytes.
d Nonuse of littermate controls in some cases—critical in
light of recent observations of the impact of the micro-
biome on adiposity/inflammation/metabolism (Nicholson
et al., 2012), as well as on NKT cells (Olszak et al., 2012).
d Occasional use of both sexes (versus onlymales)—it is well
known that gender influences inflammation and local and
systemic metabolic indices (e.g., Macotela et al., 2009).
d Utilization of different feeding regimes—variable HFD
compositions, ages at HFD introduction, HFD durations
(ranging from 4 days to 26 weeks).
d Quantification of different readouts—for example, inflam-
mation might be assessed by flow cytometry of leuko-
cytes, macrophages, and/or T cells or by PCR titration of
cell-type-specific or inflammatory transcripts. Or, different
sites might be examined (VAT versus subcutaneous
adipose tissue versus blood), problematic because
different fat depots are known to have inherently variable
association with insulin sensitivity, inflammatory tenors,854 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.transcriptomes/proteomes, and adipocyte precursor cells,
for example (Perrini et al., 2008; Macotela et al., 2009,
2012; Alvehus et al., 2010; Tran et al., 2008).
Given these diverse issues, it seems best to reserve judgment
on the role of NKT cells in obesity-associated inflammation and
its consequences, while being open to a potentially important
role. It would be helpful to the research community if in the future
investigators would employ, and journal editors would insist on
the use of, cohoused single-sex littermates of stable genetic
background for critical comparisons.Synthesis
The complex cast of cellular characters implicated in obesity-
associated inflammation and attendant metabolic abnormalities,
and their diverse activities, are difficult for one (especially one on
the ‘‘metabolism’’ side of immunometabolism) to assimilate. The
goings-on in certain Hieronymus Bosch paintings—for example
‘‘The Garden of Earthly Delights’’ (Figure 1)—spring to mind.
What is the root of this complexity?
First, it is important to recognize that complexity is to be
expected. Inflammation is a complicated, highly orchestrated
process, wherein tissue-resident macrophages and mast cells;
recruited neutrophils, monocytes, and, in some contexts, eosin-
ophils; and eventually multiple lymphoid cell types have stereo-
typed functions to perform. In addition, the inflammatory
process, especially if it becomes chronic, is kept in check by reg-
ulatory cells of diverse types (e.g., M2-type macrophages and
Tregs). A clear understanding of how VAT inflammation unfolds
awaits definitive identification of its trigger(s). The initiating stim-
ulus for the benign inflammation of lean individuals remains
largely unexplored. Lipotoxicity, hypoxia, endoplasmic reticulum
stress, necrosis, and the microbiota have all been implicated as
initiators of the more aggressive inflammation provoked by
obesity (Donath and Shoelson, 2011; Henao-Mejia et al., 2012).
The NLRP3-containing inflammasome seems to be a critical
driver (Vandanmagsar et al., 2011; Stienstra et al., 2011;
Henao-Mejia et al., 2012). Another important issue that needs
to be resolved is precisely when T andB cells come in. It is gener-
ally thought that innate immune cells are first responders to
inflammatory stimuli, eventually calling in adaptive immune
cells—but the opposite certainly occurs (e.g., Ji et al., 2002)—
and several of the studies reviewed above implicate changes
in T cell populations as a primordial event. The skewed TCR rep-
ertoires of VAT-infiltrating T cell subsets (Nishimura et al., 2009;
Yang et al., 2010; Winer et al., 2009; Feuerer et al., 2009) suggest
that recognition of an antigen (or antigens) might be a spark.
Second, the inventory of immune cell types implicated in
obesity-associated inflammation is expanded by the participa-
tion of both effector and regulatory cells (summarized in Figure 2).
Logically, the more of the former, the more of the latter: different
regulators might be called into play at specific junctures to
control specific activities.
Third, the development of insulin resistance and type 2
diabetes is a multistage process. For several immune cell types
it is not entirely clear where they come into play. For example,
manipulations of mast cells, eosinophils, ILCs, and gd T cells
all impact body and/or VAT weight. This, in and of itself,
could promote adipose-tissue inflammation and downstream
Table 1. Variable Results Concerning NKT Cells
NKT Cell Study
NKT Effect on: NKT Manipulation Experimental Mice HFD Regime
CommentsAdiposity Inflammation Insulin Sensitivity Cd1d/ Ja18/ aGal Cer Clean Genetics?
Littermate
Controls? Gender Starting Age Duration
Ohmura et al.,
2010
no change worsened negative no no yes yes no M 8 weeks 13 weeks Relied on b2m/
mice, which also
have CD8+
T cell deficiency
Mantell et al., 2011 no change no change no change yes no no probably (N7
backcross)
yes ? ? 26 weeks
Kotas et al., 2011 no change little slightly positive
(Cd1d/)
or no change
(Ja18/)
yes yes no yes (Cd1d/),
probably (Ja18/)
(6 backcrosses)
yes M 6–8 weeks 8–16 weeks
Satoh et al., 2012 enhanced
(Cd1d/),
no change
(Ja18/ or
aGalCer)
worsened
(Cd1d/),
no change
(Ja18/)
negative
(Cd1d/),
no change
(Ja18/)
yes yes yes ? no M + F 8 weeks 14–18 weeks
Wu et al., 2012 no change
(M) or slightly
enhanced (F)
worsened negative yes yes yes yes yes M + F 5–6 weeks variable
Ji et al., 2012b no change no change
(Cd1d/),
improved
(aGalCer)
no change
(Cd1d/),
positive
(aGalCer)
on glucose
tolerance
yes no yes yes no M 6 weeks 8 weeks Mediated through
IL-4/STAT6
Ji et al., 2012a no change improved positive yes no no yes no M 6 weeks 4 days Mediated
through IL-4
Schipper et al.,
2012
little change mixed positive yes yes no yes no M 10–11 weeks 18–19 weeks Greater effects
on NC: NKT cells
improve metabolic
indices
Lynch et al., 2012 diminished improved positive yes yes yes yes no M + F 6 weeks 10 weeks
Strodthoff et al.,
2013
enhanced no change no change no yes no ? no M 5–8 weeks 10–14 weeks Effects on lipid
metabolism
mainly mediated
by liver
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Figure 1. ‘‘The Garden of Earthly Delights’’ by Hieronymus Bosch
An image that springs to mind when attempting to synthesize data on the participants and goings-on in obesity-associated inflammation.
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Perspectivemetabolic abnormalities. Such a scenario would not diminish the
interest of these cell types, but begs the question of whether their
primary effect might not rather be on nonimmunological pro-
cesses such as satiety, intestinal food absorption, macronutrient
metabolism, etc, some of which have already been associated
with IL-4, for example (Ricardo-Gonzalez et al., 2010; Orihara
et al., 2009).
Lastly, some of the complexity might reflect experimental
artifacts—inadequate cell-lineage markers, segregating genes
in genetically impure mouse lines, microbiome effects, nonuse856 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.of littermate controls, housing conditions, etc. How impactful
these issues can be was detailed above for the case of
NKT cells.
With these thoughts in mind, we offer theminimalist scheme of
Figure 2. It is clear that both pro- and anti-inflammatory cells of
both the innate and adaptive arms of the immune system are
important participants in the obesity-induced inflammation that
promotes local and systemic metabolic aberrancies. Imperative
at this point is a critical, data-based integration of these cells
and their products into a synthetic scenario. In order toFigure 2. Immune Cell Players in
Organismal Metabolism
The outcome of obesity-associated adipose-
tissue inflammation reflects a balance between
pro- and anti-inflammatory elements of the innate
and adaptive immune systems.
Cell Metabolism
Perspectiveaccomplish this task, wemust go beyond simple demonstrations
that a particular cell type or molecule is an important player to
systems-level dissections of its upstream, downstream, and
lateral interactions.
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